TYRO3 Agonists Protect Podocytes in Kidney Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for kidney and neurodegenerative diseases associated with podocyte injury lack effective therapeutic options, particularly in addressing the protective mechanisms against podocyte injury in early stages of glomerular diseases.
Innovation Solution
Development of compounds that activate TYRO3 signaling, specifically designed to target and modify TYRO3 signaling pathways in cells, thereby treating kidney and neurodegenerative diseases by administering therapeutically effective amounts of these compounds.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for kidney and neurodegenerative diseases, then existing therapeutic options are maintained, but effective treatment of podocyte injury in early stages is lacking
Solution Approach 1:
The patent changes the therapeutic parameter by targeting TYRO3 signaling pathway activation instead of using conventional treatments. The compounds disclosed modify the biochemical parameter of TYRO3 receptor activation, which mediates podocyte injury protection, thereby providing effective treatment where previous options were insufficient
Solution Approach 2:
The patent introduces small molecule compounds as intermediaries that activate TYRO3 signaling. These compounds serve as mediators between the administered drug and the podocyte injury protection mechanism, enabling therapeutic effect through TYRO3 pathway activation without directly administering proteins or biologics
2Reliability
If TYRO3 signaling is activated to protect podocytes, then renoprotective effects are achieved, but the mechanism is not yet fully understood or targeted by existing therapies
Solution Approach 1:
The patent enables the body's own TYRO3 signaling system to provide self-protection against podocyte injury. By activating the endogenous TYRO3 pathway with small molecule compounds, the therapeutic approach harnesses the body's intrinsic protective mechanisms rather than requiring complex external interventions
Solution Approach 2:
The patent modifies the signaling parameter of TYRO3 pathway activation to achieve podocyte protection. The disclosed compounds specifically tune the activation level of TYRO3 signaling, providing a controllable therapeutic parameter that can be optimized for different disease states and stages
Data Source
AI summary
The present disclosure is concerned with small molecule modulators of TYR03 signaling useful for treating various disorders such as, for example, kidney disease (e.g, chronic kidney disease, acute kidney injury (AKI), diabetic kidney disease (DKD), focal segmental glomemlosclerosis (FSGS)) and a neurodegenerative disease (e.g, amyotrophic lateral sclerosis (ALS), Alzheimer's disease, Parkinson's disease, spinal muscular atrophy, traumatic brain injury, vascular dementia, Huntington's disease, mental retardation, and attention deficit and hyperactivity disorder (ADHD)). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.